⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Dong-A Socio Holdings Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Dong-A Socio Holdings Co., Ltd.
↗Seoul, South Korea
Dong-A Socio Holdings is a major South Korean holding company established in 1932. It operates as the parent entity for a diverse group of companies primarily focused on the pharmaceutical, biopharmaceutical, and healthcare sectors, including its key subsidiary, Dong-A ST.
The group's business segments span medicine manufacturing, logistics, packaging, and management consulting. They are deeply involved in the development of innovative drugs, biomedicines, and biosimilars, with a strong commitment to improving health outcomes through R&D and global distribution.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Pharmaceuticals & Healthcare
SIZE & FINANCIALS
Employees:1001-5000
Founded:1932
Ownership:public
Status:operating
STOCK
Exchange:Korea Exchange (KRX)
Ticker:000640
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biologics, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Dong-A ST, Dong-A Pharmaceutical
COMPETITION
Position:Leader
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, Kite Pharma, Adaptive Biotechnologies
LINKS
Website:donga.co.kr
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Dong-A Socio Holdings Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.